Romere et al[11] first identified a gluconeogenic adipokine in patients with neonatal progeroid syndrome (NPS), called asprosin, which is a C‐terminal cleavage product of protofibrillin‐1 (FBN1) in the presence of proteases.[12] There is growing evidence that as a novel adipokine, asprosin may affect appetite, causing insulin resistance, and damage to pancreatic β‐cells. This evidence concerns the gene FBN1 and nail-patella syndrome.